Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
September 13, 2021 07:00 ET
|
Instil Bio
Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma Additional Cohorts: ITIL-168 clinical trial expanded during IND review process with two...
Instil Bio to Present at Upcoming Investor Conferences in September
September 02, 2021 07:00 ET
|
Instil Bio
DALLAS, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL,...
Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 12, 2021 07:00 ET
|
Instil Bio
- Presented compassionate use study in advanced melanoma demonstrating 67% of subjects achieved an objective response with 19% achieving a complete response - Received orphan drug designation from...
Instil Bio to Present at the Jefferies Virtual Healthcare Conference
June 01, 2021 07:00 ET
|
Instil Bio
DALLAS, June 01, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies...
Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 07:00 ET
|
Instil Bio
IPO in March 2021 raising $368M in gross proceeds Received orphan drug designation from the U.S. FDA for lead product candidate ITIL-168 DALLAS, May 13, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc....
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
April 27, 2021 07:00 ET
|
Instil Bio
DALLAS, April 27, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL) received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of...
Instil Bio Presents Clinical Data in Metastatic Melanoma in a Late-Breaking e-Poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting
April 12, 2021 07:18 ET
|
Instil Bio
67% overall response rate and 19% complete response rate in 21 patients All complete responders remained in remission at time of data cut-off DALLAS, April 12, 2021 (GLOBE NEWSWIRE) --...
Instil Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 23, 2021 17:00 ET
|
Instil Bio
DALLAS, March 23, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL...
Instil Bio Announces Pricing of Upsized Initial Public Offering
March 18, 2021 20:26 ET
|
Instil Bio
DALLAS, March 18, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”), a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL...